What dominates the adverse effect profile?

Gastrointestinal effects, produced by delayed gastric emptying and by area postrema signalling — both part of the mechanism.

Why is hypoglycaemia not prominent?

Because insulin secretion is amplified glucose-dependently rather than triggered independently, so it is uncommon as a monotherapy effect.

Has the profile changed since 2014?

The dominant categories have not. What has been added are events rare enough to need a large exposure base — gallbladder, gastroparesis.

GLP-1 & Incretin Science

What the Class Reliably Produces

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Gastrointestinal effects dominate the GLP-1 receptor agonist adverse effect profile and follow from the mechanism rather than from any particular molecule. Filippatos and colleagues reviewed the profile in the Review of Diabetic Studies in 2014.

Key facts

Dominant category: Gastrointestinal
Origin: The mechanism itself
Review: Filippatos 2014 (PMID 26177483)
Hypoglycaemia alone: Uncommon — glucose-dependence
Persists across: Every generation of the class
Attenuates with: Continued exposure at a stable dose

Why a 2014 review is still worth reading

It describes the profile before tirzepatide, retatrutide or the oral agents existed. That the same categories dominate a decade later is itself informative — it shows the profile is a property of engaging the receptor rather than of any compound, and that a decade of design has not changed which effects appear.

Why gastrointestinal effects dominate

Because two arms of the mechanism produce them. Delayed gastric emptying prolongs fullness and blunts the post-meal glucose rise, and it also causes nausea and early satiety. Separately, receptors in the area postrema — outside the blood-brain barrier — mediate aversive signalling. Both are the drug working.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What is conspicuously absent from the profile

Hypoglycaemia as a monotherapy effect. For a class whose purpose is lowering glucose, that absence is the notable feature, and it follows directly from glucose-dependent amplification rather than independent triggering.

How the profile has extended since

Not by adding new mechanisms so much as by accumulating events rare enough to require scale. Gallbladder events, characterised through pooled randomised trials. Gastroparesis, now systematically reviewed. The thyroid C-cell question, carried from rodent toxicology. None of these was visible in a 2014 review because the exposure base was too small.

Why attenuation matters to the profile

Gastrointestinal effects diminish with continued exposure at a stable dose, which means a rate measured early overstates the sustained experience and a rate measured late understates the initiation period. When in a trial an adverse effect is counted changes the number, independent of the compound.

The boundary

This describes published safety literature on licensed and investigational medicines given in registered trials. Nothing supplied on this site is a GLP-1 receptor agonist, and no adverse effect profile described here applies to any research material.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What dominates the adverse effect profile?: Gastrointestinal effects, produced by delayed gastric emptying and by area postrema signalling — both part of the mechanism.
Why is hypoglycaemia not prominent?: Because insulin secretion is amplified glucose-dependently rather than triggered independently, so it is uncommon as a monotherapy effect.
Has the profile changed since 2014?: The dominant categories have not. What has been added are events rare enough to need a large exposure base — gallbladder, gastroparesis.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum